A bibliometric analysis of COVID-19 publications concerning "mechanism" as a research topic in allergy journals during 2020-2021

Background: Bibliometric analysis has gained increasing interest as an efficient method to visualize COVID-19 research trends and patterns. This analysis may help to describe the profile of scientific contribution of allergy and clinical immunology specialists in the current COVID-19 pandemic. One of the arguments to support the leading role of allergists and clinical immunologists in the COVID-19 pandemic control is their expertise on disease mechanisms. We hypothesized that this role could also have an impact in the COVID-19 literature. Therefore, our objective was to compare the proportion of COVID-19 related publications dealing with the "mechanism" research topic between allergy and non-allergy journals. Method(s): This study involves a large-scale bibliometric analysis of more than 205,000 COVID-19 publications. This evaluation is embedded into the Covid Content Curation Project (0011-3638- 2020- 000001, Health Department of Navarra Government, Spain), an ongoing research to design an artificial intelligence platform for grading the relevance for decision making of COVID-19 scientific publications. We used web scraping functionalities of the Covid Content Curation platform to obtain a complete and up-to- date list of COVID-19 publications. Exclusion criteria were duplicate publications, publications from the preprint servers, publications published before March 1, 2020 or after December 31, 2021, or with any missing date data. Result(s): After exclusion criteria, 205,982 COVID-19 publications were available for analysis. The cumulative total of COVID-19 publications in allergy journals was 923 (4.48;95% CI: 4.20 to 4.78). The number of COVID-19 publications dealing with "mechanism" as a research topic was 13.22 (95% CI: 10.03 to 16.41) percentage points greater among allergy journals than non-allergy journals (p < 0.001) (Figure 1). Conclusion(s): These results show that the "mechanism" research topic is of greater prevalence in COVID-19 publications of allergy journals than non-allergy journals, and support the hypothesis that the prominent role of allergists and clinical immunologists in the COVID-19 pandemic control, based on their expertise on disease mechanisms, may also have an impact in the COVID-19 literature.

Economy: Exceptionality as a driver of structural change in the Basque Autonomous Community and Navarre

The global pandemic generated a crisis of still unpredictable consequences, further aggravated by the war in Ukraine. In 2008 a broad consensus had emerged on the need for far-reaching reforms, which basically meant doing away with the neoliberal consensus that had prevailed since the 1980s, although the chances of recovery were soon made dependent on the economic cycle. Once again, the current crisis is calling into question the quality and effectiveness of the social protection system and the welfare state itself. The responses seem to indicate a change of direction, towards safeguarding and strengthening the public sector. The Basque Country and Navarre are affected too. Two symptoms of this are the reinforcement of investment in health, which implies reversing previous cuts, and the approval of systems to cover the most disadvantaged groups. These measures require, however, the backing of other structural measures, particularly fiscal ones. © 2023, Onati International Institute for the Sociology of Law. All rights reserved.

CROSS-SECTIONAL STUDY OF MOOD AND HEALTH OF THE HEALTH WORKERS FROM THE NAVARRE-OSASUNBIDEA HEALTH SERVICE AT LEAST 6 MONTHS AFTER SUFFERING SARS-COV-2 INFECTION.

Introduction: The group of workers in the health field is essential for dealing with the pandemic. Healthcare professionals experienced an unprecedented increase in patient deaths and at the same time, had to face difficult and exceptional working conditions. A quarter of the cases diagnosed in the first months of the epidemic in Spain corresponded to workers in the health sector. Material(s) and Method(s): Non-experimental, cross-sectional study of observational research that analyzes data of variables collected through a semi-structured interview, at least 6 months after having suffered SARS-CoV-2 infection. The 17 chosen items were grouped into 3 blocks: diagnosis and evolution;psychosocial aspects;attention, follow-up and actions. LIKERT-type numerical scales were used for the items (joy, anxiety, sadness and anger). Result(s): A total of 1,490 semi-structured surveys were analyzed. By occupations, the highest percentage corresponded to nurses (32.7%), doctors (19.7%) and nursing assistants (17.2%), while the lowest percentages were those related to Administrative (11.3 %), and Wardens (4.4%), and the remaining 14.5%, grouped as TECHNICIANS. Regarding the persistence of symptoms 6 months after infection, 28.1% of those surveyed answered affirmatively. The highest percentage of workers who reported persistence of symptoms at 6 months was nursing assistants (40.8%). Discussion(s): The risk of persisting with symptoms at 6 months increases correlatively as the professional's age increases. The result obtained is in agreement with the investigations published up to now.Copyright © 2022, Accion Medica S.A.. All rights reserved.

Continuous cough monitoring with AI. Cases: treatment response, smoking cessation and COVID-19

Background: The potential of continuous cough monitoring is in an early stage, while almost every other clinical symptom has a way to be objectively monitored. Objective(s): Study if continuous cough monitoring is useful for early notice of an onset or worsening of respiratory conditions. Method(s): A free mobile application was used to detect and record cough sounds. Only 0.5s snippets of explosive sounds are sent to the server for AI to analyse. The 3 cases presented were identified within a study in Navarra, Spain. Result(s): Case 1: a 56-year-old was using the app with an average of 600 coughs/d, unknown cause. A trial with gabapentin was started, which within a month resulted in 150 coughs/d. With omeprazole added, coughing reduced to ~50 coughs/d. Case 2: a 70-year-old smoker was using the app with an average 52 coughs/day in over 2 months. She quit smoking and noticed improvements in cough, app showing 12 coughs/d. The next month, smoking relapsed, reaching 34 coughs/d. Data dynamics renewed her motivation to quit. Case 3: a 35-year-old was using the app at night, with an average of 4 coughs/hr (not self-perceived). Suddently, the patient felt general malaise and the app detected 12 coughs/hr (not self-perceived). Next day, she received a diagnosis of uncomplicated COVID-19. Conclusion(s): Cough patterns correlate with clinical progress and perceived improvement, accurately indicate signs of smoking cessation and relapse.

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Introduction: Despite recent advances in treatment, patients with multiple myeloma (MM) continue to relapse. G protein-coupled receptor family C group 5 member D (GPRC5D) is a promising target for immunotherapy in patients with MM due to its high expression in malignant plasma cells and limited expression in normal human tissue;unlike other antigens targeted by MM therapies, there is no indication that GPRC5D sheds into the periphery. Talquetamab (JNJ-64407564) is a first-in-class bispecific IgG4 antibody that redirects T cells to kill MM cells by binding to both GPRC5D and CD3 receptors. Here we report updated and new results of talquetamab at the recommended phase 2 doses (RP2Ds) from a phase 1 trial in relapsed/refractory MM (RRMM;NCT03399799). Methods: Eligible patients with MM had relapsed or refractory disease or were intolerant to standard therapies;patients previously treated with B-cell maturation antigen (BCMA)-directed therapies were eligible. This analysis focuses on patients who received talquetamab subcutaneously (SC;range 5.0-800 µg/kg) weekly or biweekly. Step-up dosing was used as a patient management strategy to minimize the severity of cytokine release syndrome (CRS). The primary objectives were to identify the RP2D (part 1) and assess talquetamab safety and tolerability at the RP2Ds (part 2). Adverse events (AEs) were graded by CTCAE v4.03 with CRS events graded per Lee et al 2014 criteria. Responses were investigator-assessed per International Myeloma Working Group criteria. Results: As of July 19, 2021, 95 patients have received SC talquetamab. The RP2D was originally identified as a weekly SC dose of 405 µg/kg talquetamab with step-up doses. However, alternative dosing schedules that require less frequent administration continue to be investigated. A biweekly RP2D was also identified as an SC dose of 800 µg/kg talquetamab with step-up doses. 30 patients received the 405 µg/kg weekly dosing schedule (median age: 61.5 years [range 46-80];63% male;100% triple-class exposed;80% penta-drug exposed;77% triple-class refractory, 20% penta-drug refractory;30% prior BCMA-directed therapy;median follow-up: 7.5 mo [range 0.9-15.2]). 23 patients received the 800 µg/kg biweekly dosing schedule (median age: 60.0 years [range 47-84];48% male;96% triple-class exposed;70% penta-drug exposed;65% triple-class refractory, 22% penta-drug refractory;17% prior BCMA-directed therapy;median follow-up 3.7 mo [range 0.0-12.0]). There were no treatment discontinuations due to AEs at either of the RP2Ds. The most common AEs at the 405 µg/kg weekly dose were CRS (73%;1 patient had grade 3 CRS), neutropenia (67%;grade 3/4: 60%), and dysgeusia (60%;grade 2: 29%);skin-related AEs occurred in 77% (all grade 1/2;nail disorders: 30%) of patients, and infections occurred in 37% of patients (1 patient had grade 3 COVID-19 pneumonia). The most common AEs at the 800 µg/kg biweekly dose were CRS (78%;all grade 1/2), dry mouth (44%;all grade 1/2), and neutropenia (44%;grade 3/4: 35%);skin-related AEs occurred in 65% of patients (grade 3: 13%;nail disorders: 17%) and infections occurred in 13% of patients (1 patient had grade 3 pneumococcal sepsis). In 30 response-evaluable patients treated with the 405 µg/kg weekly dose, the overall response rate (ORR) was 70% (very good partial response or better [≥VGPR] rate: 57%). In 17 response-evaluable patients treated with the 800 µg/kg biweekly dose, the ORR was 71% (≥VGPR rate: 53%). Responses were durable and deepened over time in both cohorts (Figure). Median duration of response (DOR) was not reached at either RP2D;the 6-month DOR rate for patients who received the 405 µg/kg weekly dose was 67% [95% CI: 41-84]. Serum trough levels of talquetamab were comparable at both RP2Ds. Consistent with the mechanism of action for talquetamab, pharmacodynamic data from cohorts treated at both dose levels showed peripheral T-cell activation and induction of cytokines. Conclusions: These findings indicate that SC talquetamab is well tolerated and highly effective at both RP2Ds. Preliminary data from the 800 µg/kg biweekly cohorts indicate that less frequent, higher doses of SC talquetamab do not have a negative impact on the previously described safety profile. Further investigation of talquetamab as monotherapy (phase 2;NCT04634552) and in combination with other therapies in patients with RRMM is underway. [Formula presented] Disclosures: Krishnan: MAGENTA: Consultancy;BMS: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau;JANSSEN: Consultancy, Research Funding;City of Hope Cancer Center: Current Employment;REGENERON: Consultancy;SANOFI: Consultancy;GSK: Consultancy;Amgen: Speakers Bureau. Minnema: Celgene: Other: Travel expenses;Alnylam: Consultancy;Cilag: Consultancy;BMS: Consultancy;Janssen: Consultancy;Kite/Gilead: Consultancy. Berdeja: Lilly, Novartis: Research Funding;Abbvie, Acetylon, Amgen: Research Funding;Celularity, CRISPR Therapeutics: Research Funding;EMD Sorono, Genentech: Research Funding;Poseida, Sanofi, Teva: Research Funding;Bluebird bio, BMS, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, SecuraBio, Takeda: Consultancy;GSK, Ichnos Sciences, Incyte: Research Funding. Oriol: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees;Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees;GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. van de Donk: Roche: Consultancy;Takeda: Consultancy;Cellectis: Research Funding;Amgen: Consultancy, Research Funding;Janssen: Consultancy, Research Funding;BMS/Celgene: Consultancy, Honoraria;Novartis /bayer/servier: Consultancy. Rodriguez-Otero: Clínica Universidad de Navarra: Current Employment;Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees;Pfizer: Consultancy;Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees;Kite: Honoraria, Membership on an entity's Board of Directors or advisory committees;Amgen: Honoraria;Regeneron: Honoraria. Askari: Janssen: Research Funding. Mateos: Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees;Sea-Gen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees;Regeneron: Honoraria, Membership on an entity's Board of Directors or advisory committees;Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees;Celgene - Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees;Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees;Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees;Oncopeptides: Honoraria;Bluebird bio: Honoraria;AbbVie: Honoraria;GSK: Honoraria;Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees;Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Costa: BMS: Consultancy, Honoraria, Research Funding;Janssen: Consultancy, Honoraria, Research Funding;Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau;Karyopharm: Consultancy, Honoraria;Pfizer: Consultancy, Honoraria;Sanofi: Consultancy, Honoraria, Speakers Burea . Verona: Janssen: Current Employment. Ma: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Girgis: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Yang: Janssen: Current Employment. Hilder: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Russell: Janssen: Ended employment in the past 24 months. Goldberg: Janssen: Current Employment, Current holder of individual stocks in a privately-held company. Chari: Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees;Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding;Millenium/Takeda: Consultancy, Research Funding;Sanofi Genzyme: Consultancy, Membership on an entity's Board of Directors or advisory committees;Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees;BMS/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Antengene: Consultancy, Membership on an entity's Board of Directors or advisory committees;Takeda: Consultancy, Research Funding;Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Pharmacyclics: Research Funding;Secura Bio: Consultancy, Membership on an entity's Board of Directors or advisory committees;Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees;AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees;GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees;Novartis: Consultancy, Research Funding;Genentech: Consultancy, Membership on an entity's Board of Directors or advisorycommittees;Janssen Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.